Effectiveness of bio-regulators in the treatment of diabetic retinopathy.

Trofimova SV, Khavinson VKh. Vestn Oftalmol. 2001.

Organ: retina-vision · Type: clinical · Peptides: Retinalamin, Epithalamin, Cortexin

A 2001 comparative series (104 patients on Retinalamin, Epithalamin, and Cortexin vs 42 controls) reporting improved acuity, fundus picture, and retinal blood flow in diabetic retinopathy — not a modern masked RCT.

Editorial summary of a 2001 original article in Vestnik Oftalmologii (Russian title with English abstract). PubMed indexes the paper as a comparative study. Public pages cite PubMed only. Read the paper: PMID 11521426.

Methods

One hundred four patients received bioregulatory therapy (retinal preparation Retinalamin, pineal preparation Epithalamin, cerebral-cortex preparation Cortexin) and 42 patients were controls. The English abstract does not describe randomization, masking, dose, or duration. Those details belong in the primary text.

Findings

The authors report that peptide bioregulators in 90% of cases promoted improvement of visual acuity, improved the ophthalmoscopic picture of the fundus (resolution of hemorrhages and plasmorrhages, decreased macular edema), and in all cases improved functional activity of the retina and retinal blood flow. They report no negative clinical changes after the peptides, and they describe normalized carbohydrate metabolism (blood sugar and glycosylated hemoglobin), phagocytosis, and subjective well-being. They interpret this as a pathogenetic effect.

This is a 2001 unmasked comparative series from the originating group. It is not current diabetic-retinopathy guideline evidence. Follow the PMID.